Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale?
Enrica T. Tanda(Ospedale Policlinico San Martino), Paola Queirolo, Elena Croce(Ospedale Policlinico San Martino), Francesco Spagnolo(Martin University), Giovanni Rossi(Ospedale Policlinico San Martino), Andrea Boutros(The University of Sydney), Federica Cecchi(Ospedale Policlinico San Martino), Agostina Lagodin d’Amato(Ospedale Policlinico San Martino)
Cited by 29
Related Papers
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2017|491
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
|The Lancet Oncology|2021|389
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility
|Nature Genetics|2020|238
The treatment of advanced melanoma: Current approaches and new challenges
|Critical Reviews in Oncology/Hematology|2024|140
Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy
|Seminars in Cancer Biology|2019|119